A Phase II Study of Eltrombopag as a Novel Therapeutic Approach for Patients With Low-risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) With TET2 Mutations
This study is testing an FDA-approved drug called eltrombopag to see if it can help improve blood cell counts in patients with certain low-risk blood conditions like myelodysplastic syndromes and chronic myelomonocytic leukemia that have specific gene changes called TET2 mutations. Researchers want to see if this medicine can help the body produce healthier blood cells while also stopping the growth of mutated cells.
You may be able to join if you are 18 or older, have a confirmed diagnosis of lower-risk myelodysplastic syndromes or a specific early stage of chronic myelomonocytic leukemia, and have low red or white blood cell counts. People with high-risk disease, previous treatments with certain drugs, or bone marrow scarring cannot participate.
Participants will take the study medication, eltrombopag, which helps encourage the body to make certain blood components like platelets. Your health team will closely monitor your blood counts and track any changes in your genes over time during scheduled visits.
The study takes place in Cleveland, Ohio, United States, and is currently suspended.
- 1Testing a medication called eltrombopag for specific low-risk blood conditions.
- 2Aims to improve blood cell counts and study the effects on TET2 gene mutations.
- 3Currently suspended and takes place in Cleveland, Ohio.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.